D)osage
Chirico et al showed that 500 mg/kg Sandoglobulin given to preterm infants under 1500 g raised the mean serum IgG concentration to over 13 g/l, with a serum half life of 260 hours.5 Antibody titres to E coli rose to a concentration that is normally protective, and with a serum half life of 112 hours. Antibody titres to group B streptococcus rose to normally protective concentrations with a serum half life of 82 hours, and antibody to cytomegalovirus also rose appreciably with a serum half life of 112 hours. Noya et al studied pharmacokinetics of Gammagard in 20 infants weighing 750-1500 g during the first week.6 Mean IgG rose from around 5 g/l to over 13 g/l (equal to the concentrations in full term infants or adults) 15 minutes after infusion of 500 mg/kg. Mean IgG had fallen to 7-3 g/l by 7 days, to 6-1 g/l by 14 In another prophylactic trial, 500 mg/kg of Sandoglobulin was given intravenously weekly for one month to infants weighing less than 1500 g in a randomised open trial (83 infants).5 Only two of the treated infants (5%) developed septicaemia compared with eight of the control group (20%). Of the control group 15% died with infection as the main cause, compared with 2% of the treated group. The same investigators carried out a prophylactic trial in infants over 1500 g who were receiving intensive care and found no difference in outcome. 5 Stabile et al carried out an open randomised prophylactic trial in which they gave 500 mg/kg of Venogamma Polivalente on the first, second, third, seventh, 14th, 21st, and 28th days in 94 preterm infants with a mean gestational age of 31 weeks and a mean birth weight of 1340 g.'0 They found no difference in the incidence of sepsis or mortality between the two treatment groups. The results of this trial are perhaps not directly applicable to very preterm infants in other countries because many of the infants were over 1500 g or 30 weeks, the range of organisms was unusual with not a single case of group B streptococcus or E coli, and the immunoglobulin preparation is different from that used in all other neonatal studies and is not available in most countries. Didato et al carried out a prophylactic trial of intravenous IgG but with insufficient statistical power (only 37 infants under 1500 g); no significant difference was found. " Sidiropoulos et al carried out a randomised open 'rescue' trial in infants ill with suspected sepsis. 2 Sandoglobulin was given to half the preterm infants in a dose of 500 mg/day for a total of six days. Sepsis was confirmed in 22 preterm infants. Four out of nine preterm infants in the control group and one out of 13 preterm infants in the group receiving immunoglobulin died (p<004).
Haque et al carried out a double blind 'rescue' trial.'3 Sixty infants ill with suspected sepsis (later confirmed in 44)
were randomised and 250 mg/kg Pentaglobin was given daily to half the infants. Mortality from sepsis was significantly higher, being six out of 30 (20%) in the control group, and one out of 30 (3%) in the immunoglobulin treated group.
Conclusion
The published evidence shows a pronounced, prolonged deficiency of immunoglobulin in very preterm infants, which places them at increased risk of bacterial sepsis. Highly purified and apparently safe intravenous immunoglobulin preparations can restore serum IgG concentrations to those of full term infants or adults. Two out of four randomised trials concluded that prophylaxis could reduce septicaemia in infants weighing <1500 g and two 'rescue' trials have shown improved survival in septic neonates. Large randomised trials are in progress in the United States.
Whether neonatologists opt to use IgG prophylactically in the highest risk group (those weighing under 1000 g receiving intensive care) will depend on the background incidence of bacterial sepsis in their own neonatal units. There are other ways of reducing the incidence of sepsis, such as recruiting adequate numbers of qualified nurses, strict handwashing, and avoidance of invasive procedures.
Further research is needed on the minimum effective dosage and the interval between doses, but in units where infection is common in very low birthweight infants it is reasonable (on available data) to treat prophylactically with 500 mg/kg on admission and to repeat treatment every one to two weeks. In the absence of hypovolaemia, IgG should be given slowly over three hours, as the volume of Sandoglobulin is 17 ml/kg with 2-5 mmol of sodium/kg. In the United Kingdom, Sandoglobulin costs £19-50 for 1 g and £46-80 for 3 g. We have found that treating two or three infants out of the same bottle on the same day reduces the cost to acceptable levels. Alternative approaches would be to monitor serum concentrations of IgG weekly in infants weighing under 1500 g and treating infants whose concentrations fell below 3-0 g/l,14 or to reserve IgG for immediate use in very low birthweight infants who became ill with suspected sepsis. Whichever policy is adopted, IgG will not protect against all types of infection. Fresh frozen plasma is also required to restore complement dependent opsonisation fully. In the future, human monoclonal antibody preparations against the common perinatal pathogens will probably provide more effective treatments in smaller volumes of fluid. ' 
